CO5590926A2 - Uso de anastrozol para el tratamiento de mujeres posmenopausicas que tienen cancer precoz de mama - Google Patents
Uso de anastrozol para el tratamiento de mujeres posmenopausicas que tienen cancer precoz de mamaInfo
- Publication number
- CO5590926A2 CO5590926A2 CO04064979A CO04064979A CO5590926A2 CO 5590926 A2 CO5590926 A2 CO 5590926A2 CO 04064979 A CO04064979 A CO 04064979A CO 04064979 A CO04064979 A CO 04064979A CO 5590926 A2 CO5590926 A2 CO 5590926A2
- Authority
- CO
- Colombia
- Prior art keywords
- use according
- cancer
- anastrozole
- breast cancer
- woman
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical Treatment Of Metals (AREA)
Abstract
1.- El uso de anastrozol, o una sal farmacéuticamente aceptable del mismo, en la preparación de un medicamento para la reducción de la tasa de recurrencia de cáncer en una mujer posmenopáusica que tiene cáncer precoz de mama.2.- El uso de anastrozol, o una sal farmacéuticamente aceptable del mismo, en la preparación de un medicamento para la reducción de la tasa de un nuevo tumor primario contralateral en una mujer posmenopáusica que tiene cáncer precoz de mama.3.- El uso de acuerdo con Reivindicación 1 o Reivindicación 2 en donde el anastrozol se suministra sustancialmente en ausencia de un agente antiestrógeno.4.- El uso de acuerdo con Reivindicación 3 en donde el agente antiestrógeno es tamoxifeno.5.- El uso de acuerdo con una cualquiera de las Reivindicaciones precedentes en donde la mujer que tiene dicho cáncer precoz de mama es positiva de receptor de estrógeno o positivas de receptor de progesterona.6.- El uso de acuerdo con Reivindicación 5 en donde la mujer que tiene dicho cáncer precoz de mama es positiva de receptor de estrógeno y positiva de receptor de progesterona.7.- El uso de acuerdo con una cualquiera de las Reivindicaciones precedentes en donde el anastrozol se provee para administración en una dosis de 1 mg/por día.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0129457.8A GB0129457D0 (en) | 2001-12-10 | 2001-12-10 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5590926A2 true CO5590926A2 (es) | 2005-12-30 |
Family
ID=9927290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04064979A CO5590926A2 (es) | 2001-12-10 | 2004-07-08 | Uso de anastrozol para el tratamiento de mujeres posmenopausicas que tienen cancer precoz de mama |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20050165081A1 (es) |
| EP (2) | EP1455781B1 (es) |
| JP (2) | JP5335173B2 (es) |
| KR (1) | KR100858946B1 (es) |
| CN (1) | CN100408036C (es) |
| AT (1) | ATE406160T1 (es) |
| AU (1) | AU2002347371B2 (es) |
| BR (1) | BR0214798A (es) |
| CA (1) | CA2468965C (es) |
| CO (1) | CO5590926A2 (es) |
| CY (1) | CY1108462T1 (es) |
| DE (1) | DE60228616D1 (es) |
| DK (1) | DK1455781T3 (es) |
| ES (1) | ES2303811T3 (es) |
| GB (1) | GB0129457D0 (es) |
| HK (1) | HK1069335A1 (es) |
| HU (1) | HUP0402023A3 (es) |
| IL (1) | IL162150A0 (es) |
| IS (1) | IS7300A (es) |
| MX (1) | MXPA04005394A (es) |
| NO (1) | NO20042912L (es) |
| NZ (1) | NZ533106A (es) |
| PL (1) | PL369411A1 (es) |
| PT (1) | PT1455781E (es) |
| RU (1) | RU2320339C2 (es) |
| SI (1) | SI1455781T1 (es) |
| UA (1) | UA79443C2 (es) |
| WO (1) | WO2003053438A1 (es) |
| ZA (1) | ZA200404260B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0129457D0 (en) * | 2001-12-10 | 2002-01-30 | Astrazeneca Ab | Method of treatment |
| WO2005089511A2 (en) * | 2004-03-19 | 2005-09-29 | Transform Pharmaceuticals, Inc. | Novel pharmaceutical forms, and methods of making and using the same |
| WO2005117864A1 (en) * | 2004-05-28 | 2005-12-15 | Astrazeneca Ab | Combination product comprising anastrozole and a dual prenyl transferase inhibitor |
| CN100337625C (zh) * | 2004-08-30 | 2007-09-19 | 鲁南制药集团股份有限公司 | 阿那曲唑的分散片剂型 |
| CN1304054C (zh) * | 2004-12-29 | 2007-03-14 | 山东蓝金生物工程有限公司 | 一种缓慢释放的抗癌药物组合物 |
| GB0517673D0 (en) * | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
| GB0517674D0 (en) * | 2005-08-31 | 2005-10-05 | Astrazeneca Ab | Formulation |
| WO2011130381A1 (en) * | 2010-04-13 | 2011-10-20 | Estrocept Diagnostics, Inc. | Diagnostic assays for breast cancer treatment and progression |
| US10201549B2 (en) | 2013-06-14 | 2019-02-12 | Professional Compounding Centers Of America (Pcca) | Testosterone combined with anastrozole injection solutions |
| CN103450099B (zh) * | 2013-09-06 | 2015-03-25 | 杭州华东医药集团新药研究院有限公司 | 阿那曲唑及其一水合物的新晶型、制备和用途 |
| RU2548722C1 (ru) * | 2013-12-06 | 2015-04-20 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Противоопухолевое лекарственное средство пролонгированного действия на основе противоопухолевого препарата, ингибитора синтеза эстрогенов - анастрозола |
| DE102014005513B4 (de) * | 2014-04-15 | 2018-03-15 | Sanoxsys Gmbh | Mittel zur Prävention und Therapie von Tumorerkrankungen |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8714013D0 (en) * | 1987-06-16 | 1987-07-22 | Ici Plc | (substituted-aralkyl)heterocyclic compounds |
| AR034142A1 (es) * | 2000-09-08 | 2004-02-04 | Sloan Kettering Inst Cancer | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion |
| GB0129457D0 (en) * | 2001-12-10 | 2002-01-30 | Astrazeneca Ab | Method of treatment |
-
2001
- 2001-12-10 GB GBGB0129457.8A patent/GB0129457D0/en not_active Ceased
-
2002
- 2002-06-12 UA UA20040705521A patent/UA79443C2/uk unknown
- 2002-12-06 BR BR0214798-0A patent/BR0214798A/pt not_active Application Discontinuation
- 2002-12-06 JP JP2003554195A patent/JP5335173B2/ja not_active Expired - Lifetime
- 2002-12-06 EP EP02783305A patent/EP1455781B1/en not_active Revoked
- 2002-12-06 IL IL16215002A patent/IL162150A0/xx unknown
- 2002-12-06 PL PL02369411A patent/PL369411A1/xx not_active Application Discontinuation
- 2002-12-06 CA CA2468965A patent/CA2468965C/en not_active Expired - Fee Related
- 2002-12-06 US US10/498,444 patent/US20050165081A1/en not_active Abandoned
- 2002-12-06 PT PT02783305T patent/PT1455781E/pt unknown
- 2002-12-06 CN CNB02824544XA patent/CN100408036C/zh not_active Ceased
- 2002-12-06 ES ES02783305T patent/ES2303811T3/es not_active Expired - Lifetime
- 2002-12-06 DK DK02783305T patent/DK1455781T3/da active
- 2002-12-06 NZ NZ533106A patent/NZ533106A/xx not_active IP Right Cessation
- 2002-12-06 AT AT02783305T patent/ATE406160T1/de active
- 2002-12-06 DE DE60228616T patent/DE60228616D1/de not_active Expired - Lifetime
- 2002-12-06 SI SI200230746T patent/SI1455781T1/sl unknown
- 2002-12-06 HU HU0402023A patent/HUP0402023A3/hu not_active Application Discontinuation
- 2002-12-06 MX MXPA04005394A patent/MXPA04005394A/es active IP Right Grant
- 2002-12-06 RU RU2004121162/15A patent/RU2320339C2/ru not_active IP Right Cessation
- 2002-12-06 EP EP08162209A patent/EP1997492A1/en not_active Withdrawn
- 2002-12-06 KR KR1020047008806A patent/KR100858946B1/ko not_active IP Right Cessation
- 2002-12-06 AU AU2002347371A patent/AU2002347371B2/en not_active Revoked
- 2002-12-06 WO PCT/GB2002/005554 patent/WO2003053438A1/en active IP Right Grant
-
2004
- 2004-05-31 ZA ZA2004/04260A patent/ZA200404260B/en unknown
- 2004-06-04 IS IS7300A patent/IS7300A/is unknown
- 2004-07-08 CO CO04064979A patent/CO5590926A2/es not_active Application Discontinuation
- 2004-07-09 NO NO20042912A patent/NO20042912L/no not_active Application Discontinuation
-
2005
- 2005-03-08 HK HK05101996.7A patent/HK1069335A1/xx not_active IP Right Cessation
-
2008
- 2008-10-29 CY CY20081101221T patent/CY1108462T1/el unknown
-
2010
- 2010-09-06 JP JP2010199008A patent/JP2011016828A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kolvenbag et al. | Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer | |
| CO5590926A2 (es) | Uso de anastrozol para el tratamiento de mujeres posmenopausicas que tienen cancer precoz de mama | |
| HU221589B (hu) | Emlő- és méhrák kezelésére alkalmas kombinációs gyógyszerkészítmény és eljárás előállítására | |
| HRP20070188B1 (hr) | Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva | |
| AR031563A1 (es) | Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u | |
| JP2017039771A5 (es) | ||
| BRPI0516243B8 (pt) | uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit | |
| CO6260084A2 (es) | Una composicion farmaceutica que comprende un precursor de esteroide sexual de deshidroepiandrosterona (dhea) | |
| PT836506E (pt) | Penso transdermico para administracao de 17-desacetil norgestimato so ou em combinacao com um estrogenio | |
| EA200900491A1 (ru) | Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола | |
| EP0641565A1 (en) | Contraceptive and menstrual cycle controlling drug having oncostatic properties | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| PE20031047A1 (es) | Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama | |
| Bus et al. | Treatment of mesenteric desmoid tumours with the anti-oestrogen ic agent toremifene: case histories and an overview of the literature | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| AR009113A1 (es) | UN PRODUCTO ANTICONCEPTIVO PARA DETENER LA OVULACIoN EN MUJERES DURANTE SU PERIODO DE ACTIVIDAD OVÁRICA | |
| SV2002000179A (es) | Proceso para la preparacion de un compuesto para reducir el riesgo del cancer ref.x-13527-el | |
| ES2320662T3 (es) | Hormonoterapia restitutiva y tratamiento para la depresion con dienogest. | |
| HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| AR049195A1 (es) | Uso de una combinacion de etinilestradiol y acetato de clormadinona para la preparacion de un medicamento | |
| HUP0101005A2 (hu) | Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére | |
| Espie | Megestrol acetate in advanced breast carcinoma | |
| AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación | |
| Misra | Nasal route for delivery of emergency contraceptives | |
| CL2004000579A1 (es) | Uso de dienogest para preparar composiciones farmaceuticas destinadas a reducir el cuerpo de la glandula mamaria. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |